Drug Trial Radar · NCT02847637
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Sep 27, 2016
Primary completion
Sep 15, 2017
Study completion May 12, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Chugai Pharmaceutical
- First posted
- Jul 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.
Conditions
- Hemophilia A
Interventions
EmicizumabDrug
Participants received emicizumab prophylaxis subcutaneously at the specified dose for each arm. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol version 4 (20-Dec-2019), treatment duration was extended. During this study prolongation, each participant had the option to choose a preferred emicizumab dosing regimen among those permitted (i.e., emicizumab 1.5 mg/kg once every week \[QW\], 3 mg/kg once every 2 weeks \[Q2W\], or 6 mg/kg once every 4 weeks \[Q4W\]) and continue on that dosing regimen until discontinuation from the study.
Factor VIII (FVIII)Drug
FVIII was allowed to treat bleeds on an episodic basis, per the local prescribing information. Specific dosages of FVIII were not mandated in the study. Breakthrough bleeds were to be treated with the lowest FVIII dose expected to achieve hemostasis, which may have been lower than the participant's prior FVIII dose. To avoid bleeds before adequate emicizumab level is reached, patients in Arm D continued their regular FVIII prophylaxis until the second emicizumab loading dose. Concomitant routine FVIII prophylaxis was not permissible otherwise during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rate (ABR) for Treated BleedsTime frame: From Baseline to at least 24 weeks (median [min-max] efficacy periods for Arm C: 24.00 [14.4-25.0] weeks; Arm A: 29.57 [17.3-49.6] weeks; Arm B: 31.29 [3.3-50.6] weeks; Arm D: 33.14 [18.4-48.6] weeks)
Locations
39 sites in 14 countries. Site status is shown where the registry gives one.
Santa Monica Oncology Center
Santa Monica, California
Georgetown Uni Medical Center; Lombardi Cancer Center
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Winship Cancer Institute
Atlanta, Georgia
Dana-Farber Cancer Institute; Brigham and Women's Cancer Center
Boston, Massachusetts
Children's Hospital of Michigan; Pediatrics
Detroit, Michigan
Cornell Univ Medical College; Hematology-Oncolog
New York, New York
Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia
Seattle, Washington
Royal Adelaide Hospital
Adelaide, South Australia, Australia
The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit
Melbourne, Victoria, Australia
The Perth Blood Institute
Nedlands, Western Australia, Australia
ICIC
San José, Costa Rica
Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique
Bron, France
CH de Bicetre; Centre de Traitement d' Hemophilie
Le Kremlin-Bicêtre, France
Groupe Hospitalier Necker Enfants Malades
Paris, France
Universitätsklinikum Bonn; Institut für Experimentelle Hämatologie und Transfusionsmedizin
Bonn, Germany
St James's Hospital
Dublin, Ireland
IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi "Angelo Bianchi e Bonomi"
Milan, Lombardy, Italy
AOU Careggi; SOD Malattie Emorragiche
Florence, Tuscany, Italy
Nagoya University Hospital
Aichi, Japan
St. Marianna University Hospital
Kanagawa, Japan
Sendai Medical Center
Miyagi, Japan
Nara Medical University Hospital
Nara, Japan
NHO Osaka National Hospital
Osaka, Japan
Tokyo Medical University Hospital
Tokyo, Japan
Ogikubo Hospital
Tokyo, Japan
Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii
Gdansk, Poland
SPSK Nr1 Klinika Hematoo&Transpl.Szpiku
Lublin, Poland
ALVAMED Lekarskie Gabinety Specjalistyczne
Poznan, Poland
Instytut Hematologii i Transfuzjologii; Klinika Zaburzeń Hemostazy i Chorób Wewnętrznych
Warsaw, Poland
Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center
Johannesburg, South Africa
Severance Hospital
Seoul, South Korea
Hospital Universitario la Paz; Servicio de Hematologia
Madrid, Spain
Hospital Universitario Virgen del Rocio; Servicio de Hematologia
Seville, Spain
Changhua Christian Hospital
Chang-hua, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Cardiff and Vale NHS Trust
Cardiff, United Kingdom
Royal Free Hospital; Haemophilia Centre
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.